Switzerland· 69417001
Orserdu 86 mg, Filmtabletten
A elacestrant product containing elacestrantum, registered in Switzerland by Stemline Therapeutics Switzerland GmbH and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Elacestrant is registered in 14 of 19 countries.
Countries holding a registration under ATC L02BA04 (elacestrant), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Elacestrant · ATC L02BA04
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of elacestrant costs, country by country.
Normalised to the WHO defined daily dose (0.345 g), so markets compare like for like.
- Switzerland: $374.12 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Elacestrant · price per daily dose (0.345 g)
USD · FX 28 Sept 2026
- CH Switzerland$374.12
The record
At a glance
Swissmedic (Switzerland)- Active substance
- elacestrantum
- Manufacturer
- Stemline Therapeutics Switzerland GmbH
- Country
- Switzerland (CH)
- ATC code
- L02BA04
- ATC class
- Elacestrant
- Defined daily dose
- 0.345 g, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680694170017Blist 28 StkCHF 2434.55
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elacestrant in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesORSERDUStemline Therapeutics, Inc.
- CzechiaORSERDUStemline Therapeutics B.V., Amsterdam
- SpainORSERDU 86 MG COMPRIMIDOS RECUBIERTOS CON PELICULAStemline Therapeutics B.V.
- FinlandORSERDUStemline Therapeutics B.V.
- FranceORSERDU 86 mg, comprimé pelliculéSTEMLINE THERAPEUTICS (PAYS-BAS)
- BelgiumOrserdu 86 mgStemline Therapeutics
- IcelandOrserduStemline Therapeutics B.V.
- NetherlandsORSERDU 86 mg filmomhulde tablettenStemline Therapeutics B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Orserdu
- Liechtenstein · Orserdu
- Norway · Orserdu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/deeffbd7-45ab-4554-9cc6-2d7d929c4077 GET /v1/drugs/deeffbd7-45ab-4554-9cc6-2d7d929c4077?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "elacestrantum 86 mg",
"valid_from": "2025-09-01",
"limitations": "[{\"description\":\"Nur nach vorgängiger Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\\nORSERDU wird vergütet als Monotherapie zur Behandlung von postmenopausalen Frauen mit Estrogenrezeptor (ER)-positivem, HER2-negativem, lokal fortgeschrittenem oder metastasiertem Brustkrebs mit einer aktivierenden ESR1-Mutation, deren Erkrankung nach mindestens einer endokrinen Therapielinie, kombiniert mit einem CDK 4/6-Inhibitor, fortgeschritten ist, und zwar bei Krankheitsprogession nach mindestens 12 Monaten endokrine Therapie kombiniert mit einem CDK4/6-Inhibitor.<br>\\n<br>\\nDie Zulassungsinhaberin erstattet dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen erste Aufforderung hin für jede bezogene Packung ORSERDU einen festgelegten Anteil des Fabrikabgabepreises zurück. Sie gibt dem Krankenversicherer die Höhe der Rückerstattung bekannt. Die Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21763.01<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21763.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-09-01\",\"validTo\":\"2028-08-31\"},{\"description\":\"Die Packung zu 86mg wird nur zur Dosisreduktion vergütet.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-09-01\"}]",
"galenic_form": "Filmtabl 86 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2025-09-01",
"self_retention_pct": 10
}See everything about elacestrant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.